Timothy Pardee

HCRN-AML24-687

Pilot Single Arm Phase 2 study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Status

Cancer Types

Leukemia

Locations